Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNT001 in traumatic brain injury
NCT04677829Phase 1Terminated
- Sponsor
- Pinteon Therapeutics
- Start
- Mar 2021
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PNT001 in traumatic brain injury (TBI) (3 arms), sponsored by Pinteon Therapeutics. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 84 days, Incidence of Treatment Emergent Clinical Laboratory Test Abnormalities at 84 days and 4 more. Started Mar 2021; status: terminated.
02
Drugs
PNT001
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT04677829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677829.